CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT (UNAUDITED) - USD ($) $ in Thousands	Total	Securities Purchase Agreement	Cumulative Effect, Period of Adoption, Adjustment	Common Stock	Common Stock Securities Purchase Agreement	Additional Paid - In Capital	Additional Paid - In Capital Securities Purchase Agreement	Subscription Receivable	Cumulative Translation Adjustment	Accumulated Deficit	Accumulated Deficit Cumulative Effect, Period of Adoption, Adjustment
Stockholders' equity, beginning balance (in shares) at Dec. 31, 2023				9,131,252
Stockholders' equity, beginning balance at Dec. 31, 2023	$ (51,024)		$ 22	$ 1		$ 319,992		$ (698)	$ (345)	$ (369,974)	$ 22
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense (benefit)	1,070					1,070
Issuance of shares in connection with equity interest payment agreement (in shares)				45,269	450,300
Issuance of shares in connection with Equity Interest Payment Agreement	1,038	$ 1,133				340	$ 1,133	698
Restricted shares award issuance (in shares)				159,357
Issuance of warrants in connection with Securities Purchase Agreement	4,866					4,866
Foreign currency translation adjustment	(3)								(3)
Net income (loss)	(3,944)									(3,944)
Stockholders' equity ending balance (in shares) at Mar. 31, 2024				9,786,178
Stockholders equity, ending balance at Mar. 31, 2024	(46,842)			$ 1		327,401		0	(348)	(373,896)
Stockholders' equity, beginning balance (in shares) at Dec. 31, 2023				9,131,252
Stockholders' equity, beginning balance at Dec. 31, 2023	(51,024)		22	$ 1		319,992		(698)	(345)	(369,974)	22
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Reclassification of foreign currency translation adjustment realized upon liquidation of foreign subsidiary	0
Foreign currency translation adjustment	(3)
Net income (loss)	(15,879)
Stockholders' equity ending balance (in shares) at Sep. 30, 2024				10,671,337
Stockholders equity, ending balance at Sep. 30, 2024	(58,049)			$ 1		328,129		0	(348)	(385,831)
Stockholders' equity, beginning balance (in shares) at Dec. 31, 2023				9,131,252
Stockholders' equity, beginning balance at Dec. 31, 2023	$ (51,024)		$ 22	$ 1		319,992		(698)	(345)	(369,974)	$ 22
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issuance upon exercise of prefunded warrant (in shares)	810,205
Stockholders' equity ending balance (in shares) at Dec. 31, 2024	13,025,627			13,025,627
Stockholders equity, ending balance at Dec. 31, 2024	$ (55,754)			$ 1		334,330		0	(348)	(389,737)
Stockholders' equity, beginning balance (in shares) at Mar. 31, 2024				9,786,178
Stockholders' equity, beginning balance at Mar. 31, 2024	(46,842)			$ 1		327,401		0	(348)	(373,896)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense (benefit)	311					311
Common stock issuance upon exercise of prefunded warrant (in shares)				810,205
Restricted shares award issuance (in shares)				27,604
Net income (loss)	(5,568)									(5,568)
Stockholders' equity ending balance (in shares) at Jun. 30, 2024				10,623,987
Stockholders equity, ending balance at Jun. 30, 2024	(52,099)			$ 1		327,712		0	(348)	(379,464)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense (benefit)	417					417
Restricted shares award issuance (in shares)				47,350
Reclassification of foreign currency translation adjustment realized upon liquidation of foreign subsidiary	0
Foreign currency translation adjustment	0
Net income (loss)	(6,367)									(6,367)
Stockholders' equity ending balance (in shares) at Sep. 30, 2024				10,671,337
Stockholders equity, ending balance at Sep. 30, 2024	$ (58,049)			$ 1		328,129		0	(348)	(385,831)
Stockholders' equity, beginning balance (in shares) at Dec. 31, 2024	13,025,627			13,025,627
Stockholders' equity, beginning balance at Dec. 31, 2024	$ (55,754)			$ 1		334,330		0	(348)	(389,737)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense (benefit)	543					543
Issuance of shares in connection with equity interest payment agreement (in shares)				752,742
Issuance of shares in connection with Equity Interest Payment Agreement	1,370					1,370
Restricted shares award issuance (in shares)				303,549
Issuance of shares in connection with debt exchange agreements (in shares)				643,456
Issuance of shares in connection with Debt Exchange Agreements	815					815
Reclassification of foreign currency translation adjustment realized upon liquidation of foreign subsidiary	348								348
Net income (loss)	(5,564)									(5,564)
Stockholders' equity ending balance (in shares) at Mar. 31, 2025				14,725,374
Stockholders equity, ending balance at Mar. 31, 2025	$ (58,242)			$ 1		337,058		0	0	(395,301)
Stockholders' equity, beginning balance (in shares) at Dec. 31, 2024	13,025,627			13,025,627
Stockholders' equity, beginning balance at Dec. 31, 2024	$ (55,754)			$ 1		334,330		0	(348)	(389,737)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Reclassification of foreign currency translation adjustment realized upon liquidation of foreign subsidiary	348
Foreign currency translation adjustment	0
Net income (loss)	$ 2,276
Stockholders' equity ending balance (in shares) at Sep. 30, 2025	15,679,417			15,679,417
Stockholders equity, ending balance at Sep. 30, 2025	$ (49,408)			$ 1		338,052		0	0	(387,461)
Stockholders' equity, beginning balance (in shares) at Mar. 31, 2025				14,725,374
Stockholders' equity, beginning balance at Mar. 31, 2025	(58,242)			$ 1		337,058		0	0	(395,301)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense (benefit)	378					378
Issuance of shares in connection with equity interest payment agreement (in shares)				90,954
Issuance of shares in connection with Equity Interest Payment Agreement	119					119
Restricted shares award issuance (in shares)				83,807
Issuance of shares in connection with debt exchange agreements (in shares)				599,000
Issuance of shares in connection with Debt Exchange Agreements	647					647
Net income (loss)	(4,118)									(4,118)
Stockholders' equity ending balance (in shares) at Jun. 30, 2025				15,499,135
Stockholders equity, ending balance at Jun. 30, 2025	(61,216)			$ 1		338,202		0	0	(399,419)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense (benefit)	(312)					(312)
Issuance of shares in connection with equity interest payment agreement (in shares)				131,937
Issuance of shares in connection with Equity Interest Payment Agreement	162					162
Restricted shares award issuance (in shares)				48,345
Reclassification of foreign currency translation adjustment realized upon liquidation of foreign subsidiary	0
Foreign currency translation adjustment	0
Net income (loss)	$ 11,958									11,958
Stockholders' equity ending balance (in shares) at Sep. 30, 2025	15,679,417			15,679,417
Stockholders equity, ending balance at Sep. 30, 2025	$ (49,408)			$ 1		$ 338,052		$ 0	$ 0	$ (387,461)